This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. Armis Security , $200M, cybersecurity: Cybersecurity startup Armis Security closed a $200 million Series D led by Alkeon Capital and General Catalyst.
The new fund is just the latest example of investor excitement about healthcare- and biotech-related uses for AI. Venture funding to AI-related biotech and healthcare startups hit only $4.8 billion was raised by AI-related biotech/healthcare related startups. billion in 2023, a significant decrease from 2022.
Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science. imposing new export controls on biotech equipment over China concerns appeared first on OODAloop.
6 investors discuss why AI is more than just a buzzword in biotech. In her latest investor survey, Anna Heim spoke to six biotech investors about where AI creates value, short-term market shifts, and how they’d like to be approached by founders: Robert Mittendorff, M.D, general partner and head of healthcare, B Capital.
In fact, it took $200 million or more to make the list last month, as defense tech and cybersecurity led the way. NinjaOne , $500M, cybersecurity: NinjaOne, which provides endpoint management, security and monitoring, raised $500 million in Series C extensions at a $5 billion valuation more than doubling its value from just 12 months ago.
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
Biotech offerings, while more plentiful, are also running well below prior highs. Below, we pick out winners and losers for venture-backed tech and biotech companies, focusing on large- and medium-sized IPOs. Top biotech performers Biotech companies that debuted on public markets this year also saw plenty of ups and downs.
While the Boston startup scene is famous for biotech and deeptech talent, the city has lagged other hubs in creation of ultra-high-valuation AI unicorns. The largest included a $244 million Series D for Houston-based geothermal energy startup Fervo Energy and a $232 million Series C for Austin-based endpoint security provider NinjaOne.
I give credit to all the team members within my group, from help desk to infrastructure to the application and software engineers to all of Novanta team members, because you can’t do cybersecurity alone, it’s a team event. I report to the board for oversight of the cybersecurity roadmap. Then I started working. So, always be honest.
Other leading sectors included autonomous driving, healthcare, robotics, professional services, security and military, Crunchbase data shows. Large fundings were raised in multiple sectors such as AI, applied AI, energy, semiconductor, banking, security and aerospace, among others. Early stage flat Early-stage funding was flat in Q4.
That includes two cybersecurity firms and two companies in the transportation space. Island , $250M, cybersecurity: Dallas-based enterprise browser developer Island raised a $250 million Series E at a $4.8 Aura , $140M, cybersecurity: Cybersecurity has seen its fair share of big rounds this year. billion valuation.
Everything from messaging to fintech took home some cash, with the biggest round going to cybersecurity. Chainguard , $356M, cybersecurity: Software supply chain security startup Chainguard raised a massive $356 million Series D at a valuation of $3.5 billion as companies look for ways to secure software development.
Cyera , $300M, cybersecurity: After raising a $300 million Series C led by Coatue at a $1.4 billion valuation in April, data security startup Cyera closed another $300 million windfall at more than twice its previous valuation. While a cybersecurity company, Cyera is certainly riding the AI wave.
406 Ventures, and Matt Caulfield, founder and CEO of Oort, with a conversation around cybersecurity companies in Boston. To them, the area’s rich history in deep tech explains why high-tech startups, from biotech to cybersecurity companies, find success in the region. The event started with Greg Dracon, of.406
Cyera , $300M, cybersecurity: After raising a $300 million Series C led by Coatue at a $1.4 billion valuation in April, data security startup Cyera last month closed another $300 million windfall at more than twice its previous valuation. While a cybersecurity company, Cyera is certainly riding the AI wave. billion in 2021.
This year is shaping up as the first we’ve seen in which biotech and healthcare startups receive a majority of U.S. So far in 2024, biotech and health companies have pulled in around $5.6 The biotech sector’s comparatively strong showing comes as overall Series A dealmaking looks on track to come in a bit above last year’s totals.
Economic security and national security are almost directly related in the long run, said J.P. The pharmaceutical sector is a cornerstone of Americas global competitiveness, but without a serious shift in how we treat […] The post Reclaiming Americas Biotech Edge Before Its Too Late appeared first on OODAloop.
By far the largest funding recipient was San Francisco-based Xaira Therapeutics , developer of an AI platform for drug discovery that secured a $1 billion Series A last spring led by Arch Venture Partners and Foresite Capital. Ultra-large rounds Totals for this past year got a boost from a handful of ultra-large rounds.
” Marketing AI AI has had a profound effect on many sectors like biotech and cybersecurity, as many startups have added the technology to their platforms. It’s a reimagining of the job of being a marketer.” Marketing is no exception, as Hightouch is only the most recent marketing tech startup to get funding.
Of course, biotech and fintech were in there too. tied) Serán Bioscience , $200M, biotech : The big biotech raise this week went to Serán Bioscience. Picus Security , $45M, cybersecurity: San Francisco-based Picus Security, a security risk startup, closed a $45 million growth investment round led by Riverwood Capital.
Not surprisingly, those two rounds came from the cybersecurity and biotech industries. NinjaOne , $500M, cybersecurity: NinjaOne, which provides endpoint management, security and monitoring, raised $500 million in Series C extensions at a $5 billion valuation more than doubling its value from just 12 months ago.
Code, network and informationsecurity. Dear Sophie, We have a stealth early-stage biotech startup. Budding Biotech. Just enough information so that we come prepared to the meeting.”. 5 ways biotech startups can mitigate risk to grow sustainably in the long run. Product roadmap. Code quality.
lead portfolio companies for this group to go public biotechs Camp4 Therapeutics and BioAge Labs have fared poorly since their fall debuts. This includes grocery delivery service Instacart , marketing automation platform Klaviyo , and data security provider Rubrik. Meanwhile, the last U.S. Examples include Mastercard s $1.65
Kiteworks , $456M, cybersecurity: Investors seem to be digging cybersecurity yet again. A week after Abnormal Security closed a $250 million Series D that valued the startup at $5.1 Perhaps announcements are slowing as summer is coming to a close, but the week certainly seemed to lack the big money of so many this year.
Wonder ’s big $700 million raise may have captured most people’s attention last month, but the story when it came for large deals was really biotech. Mirador Therapeutics , $400M, biotech: It was a huge month for big biotech raises and this was the biggest. Check out the biggest rounds of last month here. billion valuation.
By Caleb Appleton Having invested in the biotech space since before it had a name, Ive seen life sciences investors steer founders toward a therapeutics pipeline in hopes of securing the payout of a winning drug or medical device.
The biotech didn’t specify what roles and departments got trimmed. The Washington- and Lagos-based genomics startup has been considered the showpiece of Africa’s fledging biotech space since it got into Y Combinator in 2019. Yet, 2022 will be a year to forget for the biotech startup.
The whole human proteome may be free to browse thanks to DeepMind , but at the bleeding edge of biotech new proteins are made and tested every day, a complex and time-consuming process. If everything works as advertised, Glyphic could be the new standard in protein sequencing just as demand skyrockets in the biotech world.
The week was especially good for biotech, which led the way with two big raises. Tome Biosciences , $213M, biotech: A big biotech raise hit high on the list this week. Bicara Therapeutics , $165M, biotech: If Bicara Therapeutics looks familiar, it’s because this isn’t its first time on this list.
Other noteworthy merger announcements in recent weeks include: Cancer therapy developer Veraxa Biotech announced last week that it plans to carry out a merger with a biotech-focused SPAC at a pre-money equity valuation of $1.3 billion.
national security review on UAE-based G42 ‘s minority investment in the AI chipmaker. Snyk : While many are waiting for cloud security startup Wiz to go public after its big $1 billion raise at a $12 billion valuation last year , we are going to look at another cyber firm with Israeli roots. That made sense. Companies House.
Not just fewer funds; less capital too Not only are investors raising fewer new funds; they’re securing less capital too. Quite a few are sector-focused in areas including cleantech, life sciences and cybersecurity. The rate of seed-funded companies graduating to Series A has also declined. This year, a total of $13.7
Some industries such as biotech are finding ways to use gen AI, but many enterprises experimenting with the technology have found a limited number of use cases so far, says Kjell Carlsson, head of AI strategy at Domino Data Lab, provider of an enterprise AI platform.
Aside from that, the week saw some big rounds from cybersecurity, travel and of course, biotech. Abnormal Security , $250M, cybersecurity: Abnormal Security closed a $250 million Series D that now values the San Francisco-based cybersecurity startup at $5.1 billion valuation it received after its massive $1.5
Cyberlink is the developer of the machine learning-based FaceMe Facial Recognition Engine, which is used in AIoT applications, including security, smart retail and surveillance. Planet Technology is building a secure network called PLANET Powerful Enterprise VPN Cybersecurity and Firewall Solutions for the “post-COVID-19 era.”
The city appears to be strong in areas such as travel, AI, cybersecurity, fintech, agritech, travel tech, biotech, sports tech, and VR. GoHub for B2B in AI, 5G, cybersecurity and sustainability. There are a lot of people with capabilities in AI and cybersecurity. Which are the most interesting startups in your city?
tied) Wiz , $1B, cybersecurity: Finally, something that is not AI. Cloud security startup Wiz locked up the biggest cybersecurity round of the year thus far as it raised $1 billion at a $12 billion valuation. In April, it acquired New York-based cloud detection and response startup Gem Security. billion so far.
Healthcare and biotech was the third-highest sector for new unicorns with nine companies. Robotics and cybersecurity each added six new companies. Fintech was the next-largest sector, with 12 companies in banking, payments, credit and wealth management. Energy and Web3 each minted eight new unicorns.
All 10 rounds hit $100 million or more, this time with space tech and biotech leading the way. Third Arc Bio , $165M, biotech: Biotech also saw a huge Series A this week. The biotech startup is developing therapeutics for solid tumors and inflammatory and immunology disease. So basically, that gets them on the list.
Cyera , $300M, cybersecurity: While it is true cybersecurity funding has significantly slowed , it certainly has not dried up. Data security startup Cyera raised a $300 million Series C led by Coatue at a $1.4 The biotech startup raised a $100 million Series A co-led by Arch Venture Partners and Sofinnova Investments.
Understanding the Unique Challenges of Biotech Leadership Recruitment Organizations face some unique challenges when it comes to leadership recruitment in the biotech space. Navigating these unique challenges in biotech leadership recruitment requires a comprehensive understanding of the industry, its trends, and specific needs.
Latigo Biotherapeutics , $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers. Curevo , $110M, biotech: Seattle-based Curevo, a clinical-stage biotechnology company developing vaccinations for infectious disease, closed a $110 million Series B led by new investor Medicxi.
“These are critical areas to achieve food security and promote sustainable agriculture. We believe that Boost’s platform generates a unique data set that can be exploited for far superior products with many diverse microbiome applications in food and agriculture,” said Yota Hayama, an investor at UMI, in a statement.
tied) Prolific Machines , $55M, biotech: Unlike in previous weeks, there was no huge biotech round. The startup plays at a unique intersection of healthcare/biotech, AI and 3D technology. tied) Osteal Therapeutics , $50M, biotech: Dallas-based Osteal Therapeutics raised a $50 million Series D led by Zimmer Biomet.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content